Skip to main content
Top
Published in: Supportive Care in Cancer 8/2018

01-08-2018 | Review Article

Systematic review and meta-analysis investigating the efficacy and safety of probiotics in people with cancer

Authors: Hadeel Hassan, M. Rompola, A. W. Glaser, S. E. Kinsey, R. S. Phillips

Published in: Supportive Care in Cancer | Issue 8/2018

Login to get access

Abstract

Background/objectives

Probiotics are living microorganisms that confer a health benefit on the host when administered. This systematic review and meta-analysis investigates the efficacy and safety of probiotics in adult and paediatric patients diagnosed with cancer.

Methods

A systematic review and meta-analysis was undertaken (PROSPERO registration: CRD42016050252). Randomised controlled trials (RCT), identified through screening multiple databases were included for analysis of efficacy. Non-randomised controlled trials and case reports were included for safety analysis. Outcomes included the reduction in the incidence and severity of diarrhoea, and adverse events. Where possible, data were combined for meta-analysis using a random-effects model. Planned subgroup analyses were not possible through marked heterogeneity of study characteristics.

Results

Twenty one studies (N = 2982 participants) were included for assessment of efficacy. Probiotics may reduce the incidence of diarrhoea in patients with cancer [odds ratio (OR) = 0.52, 95% confidence interval (CI) 0.34–0.78, 95% prediction interval (PI) 0.3–0.92, I-sq 36.9%, 5 studies] and the duration of pyrexia [standardised mean difference 0.39 days, 95% CI 0.35–0.43, I-sq 0.01%, 5 studies]. Twenty five studies (N = 2242) were included in the safety analysis. Five case reports showed probiotic-related bacteraemia/fungaemia/positive blood cultures. Definitions and reporting of adverse events were variable and inconsistent.

Conclusions

There remain insufficient studies to assess the true effect of probiotics in people with cancer. Meta-analysis suggests probiotics may be beneficial but further studies are still required. Improved reporting of outcomes and adverse events in clinical trials are required to improve accuracy and confidence of conclusions drawn in future updates.
Appendix
Available only for authorised users
Literature
1.
go back to reference Schlundt, J. Report of a Joint FAO/WHO Expert Consultation on Evaluation of Health and Nutritional Properties of Probiotics in Food Including Powder Milk with Live Lactic Acid Bacteria. FAO/WHO. 2012 October 2012; Available from: https://web.archive.org/web/20121022161702/http://www.who.int/foodsafety/publications/fs_management/en/probiotics.pdf Schlundt, J. Report of a Joint FAO/WHO Expert Consultation on Evaluation of Health and Nutritional Properties of Probiotics in Food Including Powder Milk with Live Lactic Acid Bacteria. FAO/WHO. 2012 October 2012; Available from: https://​web.​archive.​org/​web/​20121022161702/​http://www.who.int/foodsafety/publications/fs_management/en/probiotics.pdf
2.
go back to reference Holzapfel WH, Haberer P, Geisen R, Björkroth J, Schillinger U (2001) Taxonomy and important features of probiotic microorganisms in food and nutrition. Am J Clin Nutr 73(2 Suppl):365s–373sCrossRefPubMed Holzapfel WH, Haberer P, Geisen R, Björkroth J, Schillinger U (2001) Taxonomy and important features of probiotic microorganisms in food and nutrition. Am J Clin Nutr 73(2 Suppl):365s–373sCrossRefPubMed
3.
go back to reference Goldenberg, J.Z., et al.,(2015) Probiotics for the prevention of pediatric antibiotic-associated diarrhea. Cochrane Database Syst Rev, 22(12) Goldenberg, J.Z., et al.,(2015) Probiotics for the prevention of pediatric antibiotic-associated diarrhea. Cochrane Database Syst Rev, 22(12)
4.
go back to reference Pammi, M. and G. Suresh, Enteral lactoferrin supplementation for prevention of sepsis and necrotizing enterocolitis in preterm infants. Cochrane Database Syst Rev, 2017. 28(6) Pammi, M. and G. Suresh, Enteral lactoferrin supplementation for prevention of sepsis and necrotizing enterocolitis in preterm infants. Cochrane Database Syst Rev, 2017. 28(6)
5.
go back to reference Liu, M.M., et al.,(2017) Probiotics for prevention of radiation-induced diarrhea: a meta-analysis of randomized controlled trials. PLoS One,12(6) Liu, M.M., et al.,(2017) Probiotics for prevention of radiation-induced diarrhea: a meta-analysis of randomized controlled trials. PLoS One,12(6)
6.
go back to reference Salminen E, Elomaa I, Minkkinen J, Vapaatalo H, Salminen S (1988) Preservation of intestinal integrity during radiotherapy using live Lactobacillus acidophilus cultures. Clin Radiol 39(4):435–437CrossRefPubMed Salminen E, Elomaa I, Minkkinen J, Vapaatalo H, Salminen S (1988) Preservation of intestinal integrity during radiotherapy using live Lactobacillus acidophilus cultures. Clin Radiol 39(4):435–437CrossRefPubMed
7.
go back to reference Guarner F, Malagelada JR (2003) Role of bacteria in experimental colitis. Best Pract Res Clin Gastroenterol 17(5):793–804CrossRefPubMed Guarner F, Malagelada JR (2003) Role of bacteria in experimental colitis. Best Pract Res Clin Gastroenterol 17(5):793–804CrossRefPubMed
8.
go back to reference Arbuckle RB, Huber SL, Zacker C (2000) The consequences of diarrhea occurring during chemotherapy for colorectal cancer: a retrospective study. Oncologist 5(3):250–259CrossRefPubMed Arbuckle RB, Huber SL, Zacker C (2000) The consequences of diarrhea occurring during chemotherapy for colorectal cancer: a retrospective study. Oncologist 5(3):250–259CrossRefPubMed
9.
go back to reference Dranitsaris G, Maroun J, Shah A (2005) Estimating the cost of illness in colorectal cancer patients who were hospitalized for severe chemotherapy-induced diarrhea. Can J Gastroenterol 19(2):83–87CrossRefPubMed Dranitsaris G, Maroun J, Shah A (2005) Estimating the cost of illness in colorectal cancer patients who were hospitalized for severe chemotherapy-induced diarrhea. Can J Gastroenterol 19(2):83–87CrossRefPubMed
10.
go back to reference Redman MG, Ward EJ, Phillips RS (2014) The efficacy and safety of probiotics in people with cancer: a systematic review. Ann Oncol 25(10):1919–1929CrossRefPubMed Redman MG, Ward EJ, Phillips RS (2014) The efficacy and safety of probiotics in people with cancer: a systematic review. Ann Oncol 25(10):1919–1929CrossRefPubMed
11.
go back to reference H Hassan, M. Rompola, Bob Phillips,(2016) The efficacy and safety of probiotics in people with cancer: an updated systematic review and meta-analysis, PROSPERO H Hassan, M. Rompola, Bob Phillips,(2016) The efficacy and safety of probiotics in people with cancer: an updated systematic review and meta-analysis, PROSPERO
13.
14.
go back to reference Dissemination, C.f.R.a(2008), Systematic Reviews: CRD's guidance for undertaking reviews in health care,University of York: CRD Dissemination, C.f.R.a(2008), Systematic Reviews: CRD's guidance for undertaking reviews in health care,University of York: CRD
15.
16.
go back to reference Team, R,(2015) RStudio: integrated development for R. RStudio, Inc. Team, R,(2015) RStudio: integrated development for R. RStudio, Inc.
Metadata
Title
Systematic review and meta-analysis investigating the efficacy and safety of probiotics in people with cancer
Authors
Hadeel Hassan
M. Rompola
A. W. Glaser
S. E. Kinsey
R. S. Phillips
Publication date
01-08-2018
Publisher
Springer Berlin Heidelberg
Published in
Supportive Care in Cancer / Issue 8/2018
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-018-4216-z

Other articles of this Issue 8/2018

Supportive Care in Cancer 8/2018 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine